retatrutide safety trial results produces up to 30.3% weight loss in Phase 3 Tirzepatide vs. Retatrutide: Key Differences

ATP-binding cassette transporter subfamily C member 8 MODY (ABCC8-MODY) is a less common, but still treatment-requiring form of MODY, with the best approach to treatment being unclear

Chase JF et al

The broader treatment scope is appealing but comes without the safety and efficacy validation that Kybella provides for its approved indication

In the meantime, talk to doctor about your health goals, potential dosing and cost, and any concerns you have surrounding the conversation.

Its liposomal technology delivers glutathione directly to cells, offering a convenient and efficient alternative to intravenous administration

(PubMed) Bosch AM, Abeling NG, Ijlst L, et al